期刊文献+

结直肠癌肝转移转化治疗的相关问题 被引量:2

原文传递
导出
摘要 2012年全美约有103 170例结肠癌和40 290例直肠癌的新发病例,同年估计有51 690例患者死于结直肠癌(colorectal cancer,CRC)。国内CRC发病率和死亡率逐年上升,发病率已跃居恶性肿瘤的第3-5位。约50%-60%的CRC患者最终发生结直肠癌肝转移(colorectal liver metastases,CLM),其中同时性CLM约占20%-34%,在根治性切除术6个月后随访中出现异时性CLM约占30%-40%。
作者 赵长林
出处 《中华普通外科学文献(电子版)》 2014年第3期6-9,共4页 Chinese Archives of General Surgery(Electronic Edition)
  • 相关文献

参考文献29

  • 1Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012[J]. CA Cancer J Clin, 2012, 62(1): 10-29.
  • 2结直肠癌肝转移转化治疗中靶向药物合理应用的专家指导意见[J].中华胃肠外科杂志,2013,16(10):1000-1004. 被引量:16
  • 3Van Cutsem E, Nordlinger B, Adam R, et al. Towards a pan- European consensus on the treatment of patients with colorectal liver metastases[J]. Eur J Cancer, 2006, 42(14): 2212-2221.
  • 4Dawood O, Mahadevan A, Goodman KA. Stereotactic body radiation therapy for liver metastases[J]. Eur J Cancer, 2009, 45(17): 2947-2959.
  • 5Pawlik TM, Scoggins CR, Zorzi D, et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases[J]. Ann Surg, 2005, 241(5): 722-724.
  • 6Tsai MS, Su YH, Ho MC, et al. Clinicopathological features and prognosis in resectable synchronous and metachronous eolorectal liver metastasis[J]. Ann Surg Oncol, 2007, 14(2): 786-794.
  • 7Abdalla EK. Commentary: Radiofrequency ablation for eolorectal liver metastases: do not blame the biology when it is the technology[J]. Am J Surg, 2009, 197(6): 737-739.
  • 8张甘露(综述),袁俊波(综述),赵长林(综述).结直肠癌肝转移的新辅助治疗进展[J].国际肿瘤学杂志,2010,37(11):859-862. 被引量:3
  • 9Falcone A, Ricci S, Brunetti I, et al. Phase Ⅲ trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusianal fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest[J]. J Clin Oncol, 2007, 25(13): 1670-1676.
  • 10Souglakos J, Androulakis N, Syrigos K, et al. FOLFOXIRI (folinie acid, 5-tluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) asfirst-line treatment in metastatic colorectal cancer (MCC): a multicenlre randomised phase III trial from the Hellenic Oncology Research Group (HORG)[J]. Br J Cancer, 2006, 94(6): 798-805.

二级参考文献7

共引文献17

同被引文献14

引证文献2

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部